The Week Ahead: Fed...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$1.87 0.07 | 3.89%
06/04/12 - 09:59 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.49 | 0.58 | 0.98 |
| Price to Sales (TTM) | 3.42 | 4.62 | 1.42 |
| Price to Book (MRQ) | 0.00 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | -4.70 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -5.40 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.40 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 39.90 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -5.20 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 23.06 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -5.79 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.50 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | n.a. | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | -42.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -92.37 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -66.60 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.67 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -50.90 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -61.20 | 2.20 | 2.50 |
| Return on Investment (TTM) | -92.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -113.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 433,433.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -288,467.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 9.50 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 0.00 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.70 | 0.40 | 0.40 |
Portfolios with DYAX
- Portfolio NameUser Type
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
- Userslarsen Portfolio 1
Latest DYAX Headlines from TheStreet
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
- Dyax, RF Micro: Early Volume Plays 12.02.09 | 08:12 am
- FDA Approves Two New Drugs: BioBuzz 12.02.09 | 07:12 am
Press Releases for DYAX
- Dyax Announces Extension Of Partnership With Bayer For Access To Dyax’s Fully-Human Antibody Phage Display Library - Business Wire 05.30.12 | 08:05 am
- Dyax Corp. To Participate In The Jefferies 2012 Global Healthcare Conference - Business Wire 05.29.12 | 07:05 am
- Dyax Launches HAE Diagnostic Testing Refund Program To Encourage Proper Diagnosis And Disease Management - Business Wire 05.24.12 | 10:05 am
- "Dyax Employees Gather At Their Burlington, MA Corporate Headquarters To Take Part In The "Cover The World With Smiles" Campaign. The Initiative Asks Those From Around The World To Take A Picture Of Their 'smile', The Primary Symbol Of Hereditary Angioedema Awareness Day, To Demonstrate That People Everywhere Are Banding Together To Raise Awareness Of The Condition." (Photo: Business Wire) - Business Wire 05.16.12 | 08:05 am
- Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, A Free IPhone Application For HAE Patients - Business Wire 05.11.12 | 07:05 am
- Dyax Corp. To Participate In The Deutsche Bank 37th Annual Healthcare Conference - Business Wire 05.01.12 | 07:05 am
- Dyax Corp. To Host First Quarter 2012 Earnings Call And Webcast - Business Wire 04.18.12 | 07:04 am
- Dyax And Eclipse Therapeutics Announce Oncology Antibody License Agreement - Business Wire 04.17.12 | 07:04 am
- Dyax Launches Hereditary Angioedema Genetic Counseling Program To Educate Patients And Family Members About Disease And Inheritance - Business Wire 04.11.12 | 07:04 am
- GE Healthcare And Dyax Announce Licensing Agreement For C-Met Imaging Peptides For Use In Colorectal, Lung And Liver Cancer Research - Business Wire 03.31.12 | 08:03 am
Partner Headlines for DYAX
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
